nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

26.01.2021 | case report

Sustained remission of adult Langerhans histiocytosis utilizing molecular therapy

verfasst von: Bernhard Doleschal, Ulrich Popper

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Summary

Recent advances in molecular diagnostics classify Langerhans cell histiocytosis as an orphan disease strongly dependent on alterations in MAP kinase pathway, most prominently BRAF V600E mutation. Molecular targeted therapy with vemurafenib often leads to long-term remission. Efforts to expand therapeutic approaches include MEK inhibition or modulation of cellular senescence.

Vorheriger Artikel Autologous stem cell transplantation in light-chain amyloidosis

Nächster Artikel The emerging role of NOTCH target genes in Egyptian childhood acute lymphoblastic leukemia

Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med. 2018;379:856–68.CrossRef

Badalian-Very G, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919–23.CrossRef

Berres M, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to histiocytosis X? Br J Haematol. 2015;169:3–13.CrossRef

McClain K. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease. Hematology Am Soc Hematol Educ Program. 2020;2020(1):395–399.CrossRef

Girschikofsky M, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis. 2013;8:72.CrossRef

Baumgartner I, von Hochstetter A, Baumert B, Luetolf U, Follath F. Langerhans’-cell histiocytosis in adults. Med Pediatr Oncol. 1997;28:9–14.CrossRef

Aricò M. Langerhans cell histiocytosis in adults: more questions than answers? Eur J Cancer. 2004;40:1467–73.CrossRef

Kobayashi M, Tojo A. Langerhans cell histiocytosis in adults: advances in pathophysiology and treatment. Cancer Sci. 2018;109:3707–13.CrossRef

Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020;135:1319–31.CrossRef

10.

Christopher Z, Binitie O, Henderson-Jackson E, Perno J, Makanji RJ. Langerhans cell histiocytosis of bone in an adult: a case report. Radiol Case Rep. 2018;13:310–4.CrossRef

11.

Phillips M, Allen C, Gerson P, McClain K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009;52:97–101.CrossRef

12.

Klein C. Therapieformen der Langerhanszell Histiocytose. 2020. V‑422; DGHO.

13.

Cantu MA, et al. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012;7:e43257.CrossRef

14.

Néel A, et al. Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review. Br J Haematol. 2020; https://doi.org/10.1111/bjh.16449.CrossRefPubMed

15.

Goyal G, et al. The mayo clinic histiocytosis working group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Mayo Clin Proc. 2019;94:2054–71.CrossRef

16.

Hyman DM, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726–36.CrossRef

17.

Diamond EL, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019;567:521–4.CrossRef

18.

Kobayashi M, et al. BRAF-V600E mutation on circulating cell-free DNA is a promising biomarker of high-risk adult Langerhans cell histiocytosis. Blood. 2014;124:3209–3209.CrossRef

19.

Donadieu J, et al. Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study. J Clin Oncol. 2019;37:2857–65.CrossRef

Titel: Sustained remission of adult Langerhans histiocytosis utilizing molecular therapy
verfasst von: Bernhard Doleschal
Ulrich Popper
Publikationsdatum: 26.01.2021
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-021-00684-7

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Pain and palliative care treatment in daily practice

Physical activity and exercise in cancer patients with bone metastases

ASCO 2020: highlights in breast cancer

Obstipation and diarrhoea in palliative care—a pharmacist’s view

Genitourinary cancers—best of ASCO 2020

Short tutorial. Treatment options in light chain amyloidosis and monoclonal gammopathy of renal significance